Portal de investigación
A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine or magrolimab for patients with CD123-positive acute myeloid leukemia (AML)
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Daver, Naval Guastad
- Aribi, Ahmed M.
- Martinelli, Giovanni
- Wang, Eunice S.
- Altman, Jessica K.
- Roboz, Gail J.
- Burke, Patrick William
- Walter, Roland B.
- Begna, Kebede
- Sloss, Callum Mortimer
- Malcolm, Kara E.
- Zweidler-McKay, Patrick A.
- Sweet, Kendra Lynn
Grupos
Abstract
Abstract no disponible
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Daver,NG,Montesinos,P,Aribi,AM,Martinelli,G,Wang,ES,Altman,JK,Roboz,GJ et al. A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine or magrolimab for patients with CD123-positive acute myeloid leukemia (AML). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). 2023. Chicago. 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA:AMER SOC CLINICAL ONCOLOGY. 2023.